Nicholas (Nick) C. Nicolaides, Ph.D. is the President, Chief Executive Officer and co-founder of Navrogen™ Inc., a biopharmaceutical company developing targeted therapies for the treatment of cancer and immune-related disorders. From 2000 to 2018 he was the President, Chief Executive Officer and co-founder of Morphotek® Inc., a biopharmaceutical company specializing in the development of first-in-class antibody based products for the treatment of cancer, inflammatory and infectious diseases. 

He is a trained molecular geneticist and has authored over 70 peer-reviewed scientific papers on the molecular and genetic basis of cancer, respiratory disease and drug development and is an inventor on 80 issued patents. He received a B.S. in Biology from St. Joseph’s University, Philadelphia, PA; a Ph.D. in Human Genetics from Thomas Jefferson University, Philadelphia, PA; and a Fellowship in Oncology from Johns Hopkins University, Baltimore, MD. While at Johns Hopkins,

his research resulted in the discovery of the genetic cause of one of the most common forms of inherited cancer and the development of Morphotek’s founding platform technology called morphogenics. He has been recognized by R&D Directions’ as one of the Top 20 Most Notable People in Research and Development and received the Ernst & Young’s Entrepreneur of the Year award. In 2013, he received the Pennsylvania Governor’s Entrepreneur Impact Award for his successful biotechnology accomplishments and bringing international investment into the Pennsylvania Common Wealth.

He currently serves as an ad hoc reviewer for several immunology and cancer research journals; is a member of the American Association for Cancer Research and New York Academy of Sciences; is on the Board of Directors at Cage Pharma and is a member of several philanthropic organizations supporting the advancement of education and individuals with disabilities.